^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    LTK (Leukocyte Receptor Tyrosine Kinase)

    i
    Other names: LTK, Leukocyte Receptor Tyrosine Kinase, TYK1, Leukocyte Tyrosine Kinase Receptor, Protein Tyrosine Kinase 1, Leukocyte Tyrosine Kinase
    7ms
    Novel kinase-activating genetic events in non-small cell lung carcinomas. (PubMed, Explor Target Antitumor Ther)
    ROS1, LTK, and FGFR4 high-level overexpression was observed in 1 out of 89 tumors each. This study demonstrates the scarcity of yet unknown kinase-activating alterations in NSCLCs.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • FGFR4 (Fibroblast growth factor receptor 4) • LTK (Leukocyte Receptor Tyrosine Kinase) • RPS6KB1 (Ribosomal Protein S6 Kinase B1) • CLIP1 (CAP-Gly Domain Containing Linker Protein 1) • KAT6B (Lysine Acetyltransferase 6B) • VMP1 (Vacuole Membrane Protein 1)
    almost2years
    Spindle cell neoplasms with novel LTK fusion - Expanding the spectrum of kinase fusion-positive soft tissue tumors. (PubMed, Genes Chromosomes Cancer)
    This is the first reported case series of soft tissue tumors harboring LTK fusion, expanding the molecular landscape of soft tissue tumors driven by activating kinase fusions. Furthermore, studies involving a larger number of cases and integrated genomic analyses will be warranted to fully elucidate the pathogenesis and classification of these tumors.
    Journal
    |
    CD34 (CD34 molecule) • LTK (Leukocyte Receptor Tyrosine Kinase)
    2years
    A Study of SY-3505 in Patients With Advanced LTK Fusion-Positive Solid Tumors (clinicaltrials.gov)
    P1, N=38, Recruiting, Shouyao Holdings (Beijing) Co. LTD | Trial completion date: Dec 2025 --> May 2026 | Initiation date: Oct 2023 --> May 2024 | Trial primary completion date: Jun 2025 --> Dec 2025
    Trial completion date • Trial initiation date • Trial primary completion date • Metastases
    |
    LTK (Leukocyte Receptor Tyrosine Kinase)
    |
    ficonalkib (SY-3505)
    over2years
    A Study of SY-3505 in Patients With Advanced LTK Fusion-Positive Solid Tumors (clinicaltrials.gov)
    P1, N=38, Recruiting, Shouyao Holdings (Beijing) Co. LTD
    New P1 trial • Metastases
    |
    LTK (Leukocyte Receptor Tyrosine Kinase)
    |
    ficonalkib (SY-3505)
    3years
    Potential Drivers of Acquired Resistance to Idelalisib in CLL Patients (ASH 2022)
    We checked the phosphorylation/activation level of AKT and ERK1/2 at the responding and progression time points in the three original CLL patients with acquired resistance and observed that pERK levels are inhibited by idelalisib at baseline, but not at progression, in 2 patients (patient 1 and 2). In conclusion, we have identified potential drivers of acquired resistance to idelalisib in CLL patients, including MAPK pathway activation as in our prior study, and we continue with ongoing work evaluating the potential role of PI3K pathway mutations, BIRC3, AICDA and LTK in treatment resistance, since insights from these studies will help us guide therapy for CLL patients with refractory disease.
    Clinical • Preclinical • BRCA Biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • NRAS (Neuroblastoma RAS viral oncogene homolog) • BRCA2 (Breast cancer 2, early onset) • MAP2K1 (Mitogen-activated protein kinase kinase 1) • RB1 (RB Transcriptional Corepressor 1) • NOTCH1 (Notch 1) • SF3B1 (Splicing Factor 3b Subunit 1) • CD79B (CD79b Molecule) • FBXW7 (F-Box And WD Repeat Domain Containing 7) • BIRC3 (Baculoviral IAP repeat containing 3) • PIK3R1 (Phosphoinositide-3-Kinase Regulatory Subunit 1) • PIK3CG (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma) • IKZF3 (IKAROS Family Zinc Finger 3) • LTK (Leukocyte Receptor Tyrosine Kinase) • NFATC1 (Nuclear Factor Of Activated T Cells 1) • PDIA3 (Protein Disulfide Isomerase Family A Member 3) • DDX3X (DEAD-Box Helicase 3 X-Linked) • NFATC3 (Nuclear Factor Of Activated T Cells 3)
    |
    TP53 mutation • KRAS mutation • NRAS mutation • PIK3CA mutation • ATM mutation • RAS mutation • SF3B1 mutation • BIRC3 mutation • PIK3R1 mutation
    |
    Zydelig (idelalisib)